• Pubblicità

• Ultimi Articoli

  • Troppe grigliate, aumentano i tumori del rene.
  • “Il suo cane libero è pericoloso”. Allora gli mette le mani al collo.
  • Sustainable Picks For Laid-Back Dividend Investing
  • Giancarlo Nicoli adheres to Seeking Alpha’s Gold Standard Compliance
  • Problemi cani, Federconsumatori: troppi senza museruola e guinzaglio
  • Dendreon Corp.’s Latest Developments: What They Mean
  • Dendreon Announces CEO and Chairman Succession Plan

• Tag Cloud

  Acquistare on line AdSense Amazon.com Antenna Telecom Vodafone Azioni Beppe Grillo Brasile Cancro alla prostata Cane ferisce adulto Cani pericolosi Celiachia CMS Dendreon Dividend Ideas Dividendo DNDN Economia editoria Fabio Fittizio farmacia farmaco Finanza generico giornali informazione Internet Bookshop Italia Investing for Income Joomla! La casta bianca libertà di stampa Libri che sto scoprendo Niobe omeopatia OpenX Ordine dei Giornalisti Provenge referendum regime scoprire Seeking Alpha Stereotaxis Telefonate indesiderate Tiziano Terzani: Un altro giro di giostra vino WordPress

• Pubblicità

• Blogroll

  • Artifex -Tutto quanto fa ex libris Notizie, interviste, concorsi, artisti, premi, profili, informazioni sugli ex libris
  • Dog Bite Law Sito statunitense dedicato alle vittime di attacchi di cani

• Economia

  • Tim Harford Il sito di Tim Harford

• Finanza

  • Mercato Libero Una chiave diversa rispetto alla lettura dell’economia dei media italiani
  • Thoughts from the Frontline Il sito che diffonde la newsletter di John Mauldin

• Politica

  • Il blog di Beppe Grillo Gli italiani sentono il rumore della cascata, sanno di essere su una barca piena di buchi, ma finché non precipiteranno nelle rapide, in molti rimarranno a guardare.

di Giancarlo Nicoli

ST. LOUIS, Oct 30, 2009 /PRNewswire-FirstCall via COMTEX/ — Stereotaxis (Nasdaq: STXS) received notice that the Celsius(R) RMT ThermoCool(R) catheter has received CE Mark for distribution in the European market. The product is the fifth advanced ablation catheter resulting from the on-going co-development agreement between Stereotaxis and Biosense Webster to design and distribute magnetically enabled catheters for use in the Niobe Magnetic Navigation System (MNS).

A pre-market approval (PMA) application supplement for the Celsius(R) RMT ThermoCool(R) catheter was submitted to the U.S. Food and Drug Administration in September.

The Celsius(R) RMT and NaviStar(R) RMT families of catheters are the only magnetic catheters accurately matched to the navigational software of the Niobe(TM) MNS for optimal performance and highly precise catheter manipulation.

This catheter fills out the family of magnetic irrigated catheters to offer both localized and non-localized technology. Localized catheters are used for more complex arrhythmias requiring 3D electro-anatomic mapping for precise diagnosis, whereas non-localized catheters are typically used for simpler arrhythmias which can be treated using basic imaging and ECG recordings.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

About Forward Looking Statements

This press release includes statements that may constitute “forward- looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company’s products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

SOURCE: Stereotaxis, Inc.

di Giancarlo Nicoli

ST. LOUIS, Oct. 22 /PRNewswire-FirstCall/ — Stereotaxis, Inc. (Nasdaq: STXS) announced today that it will release its financial results for the third quarter ended September 30, 2009, on Thursday, November 5, 2009 before the market opens. The Company will host a conference call and webcast on Thursday, November 5, 2009 at 8:30 a.m. Eastern Time to discuss the Company’s third quarter results and current corporate developments. The dial-in number for the conference call is 1-877-941-8631 for domestic participants and 1-480-629-9822 for international participants.

A taped replay of the conference call will also be available beginning approximately one hour after the call’s conclusion and will be available for seven days. This replay can be accessed by dialing 1-800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4171622#. The call will also be available on the Internet live and 90 days thereafter at the following URL:

http://www.videonewswire.com/event.asp?id=63211

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The Stereotaxis system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, Canada and elsewhere.

SOURCE: Stereotaxis, Inc.

di Giancarlo Nicoli

Stereotaxis Announces Underwriters’ Exercise of Over-Allotment Option

ST. LOUIS, Oct. 12 /PRNewswire-FirstCall/ — Stereotaxis, Inc. (Nasdaq: STXS) announced today that the underwriters for the recently announced public offering of Stereotaxis common stock have exercised in full their over-allotment option to purchase an additional 975,000 shares of the Company’s common stock. The 7,475,000 shares of Stereotaxis common stock in the offering, including the 975,000 shares subject to the over-allotment option, are being sold at a price to the public of $4.00 per share.

All of the shares in the offering are being offered by Stereotaxis. The offering, including the offering of the over-allotment shares, is expected to close on October 15, 2009.

Deutsche Bank Securities Inc. and Oppenheimer & Co. Inc. are operating as joint booking-running managers for the offering.

Stereotaxis has filed a registration statement, as well as a prospectus supplement and an accompanying prospectus, with the Securities and Exchange Commission (SEC) in connection with the offering. The prospectus supplement and accompanying prospectus, when available, may be obtained by sending a request to Deutsche Bank Securities Inc., Attention: Prospectus Department, 100 Plaza One, Jersey City, NJ 07311, Telephone number: (800) 503-4611, Email: prospectusrequest@list.db.com, or to Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 300 Madison Avenue, 5th Floor, New York, NY, 10017, Telephone number: (212) 667-8563, Email: EquityProspectus@opco.com. Before you invest, you should read the prospectus supplement and accompanying prospectus, the registration statement, and the other documents that the Company has filed with the Securities and Exchange Commission for more complete information about the Company and this offering. Investors may obtain these documents for free by visiting the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, and Canada and elsewhere.

About Forward Looking Statements

This press release includes statements that may constitute “forward- looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the successful closing of the offering, the Company’s use of the proceeds of the offering, successful finalization of the Company’s previously announced extension of its revolving credit facility with Silicon Valley Bank on terms acceptable to the Company and to the bank, continued acceptance for the Company’s products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

Source: Stereotaxis, Inc.

di Giancarlo Nicoli

Stereotaxis Announces Pricing of $26 Million Common Stock Offering

ST. LOUIS, Oct. 9 /PRNewswire-FirstCall/ — Stereotaxis, Inc. (Nasdaq: STXS) announced today that it had priced the public offering of 6,500,000 shares of its common at a price to the public of $4.00 per share. Stereotaxis has granted the underwriters of the offering an option to purchase up to an additional 975,000 shares of common stock to cover over-allotments, if any. All of the shares in the offering are being offered by Stereotaxis. Stereotaxis expects the offering to close on October 15, 2009.

Deutsche Bank Securities Inc. and Oppenheimer & Co. Inc. are operating as joint booking-running managers for the offering.

Stereotaxis has filed a registration statement, as well as a prospectus supplement and an accompanying prospectus, with the Securities and Exchange Commission (SEC) in connection with the offering. The prospectus supplement and accompanying prospectus may be obtained by sending a request to Deutsche Bank Securities Inc., Attention: Prospectus Department, 100 Plaza One, Jersey City, NJ 07311, Telephone number: (800) 503-4611, Email: prospectusrequest@list.db.com, or to Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 300 Madison Avenue, 5th Floor, New York, NY, 10017, Telephone number: (212) 667-8563, Email: EquityProspectus@opco.com. Before you invest, you should read the prospectus supplement and accompanying prospectus, the registration statement, and the other documents that the Company has filed with the Securities and Exchange Commission for more complete information about the Company and this offering. Investors may obtain these documents for free by visiting the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, and Canada and elsewhere.

About Forward Looking Statements

This press release includes statements that may constitute “forward- looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the successful closing of the offering, the underwriters’ exercise of the over-allotment option, the Company’s use of the proceeds of the offering, successful finalization of the Company’s previously announced extension of its revolving credit facility with Silicon Valley Bank on terms acceptable to the Company and to the bank, continued acceptance for the Company’s products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

SOURCE: Stereotaxis, Inc.

di Giancarlo Nicoli

Stereotaxis Announces Public Offering of Common Stock

ST. LOUIS, Oct. 8 /PRNewswire-FirstCall/ — Stereotaxis, Inc. (Nasdaq: STXS) announced today that it intends, subject to market and other conditions, to offer up to $25 million of its common stock in a registered public offering pursuant to its existing shelf registration statement under the Securities Act of 1933. Stereotaxis also intends to grant the underwriters of the offering an option to purchase additional shares of common stock to cover over-allotments, if any.

Stereotaxis plans to use the proceeds from the offering for sales, marketing, and clinical support initiatives, working capital, continued research and development, and general corporate purposes.

Deutsche Bank Securities Inc. and Oppenheimer & Co. Inc. are operating as joint booking-running managers for the offering.

Stereotaxis has filed a registration statement, as well as a prospectus supplement and an accompanying prospectus, with the Securities and Exchange Commission (SEC) in connection with the offering. The prospectus supplement and accompanying prospectus may be obtained by sending a request to Deutsche Bank Securities Inc., Attention: Prospectus Department, 100 Plaza One, Jersey City, NJ 07311, Telephone number: (800) 503-4611, Email: prospectusrequest@list.db.com, or to Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 300 Madison Avenue, 5th Floor, New York, NY, 10017, Telephone number: (212) 667-8563, Email: EquityProspectus@opco.com.. Before you invest, you should read the prospectus supplement and accompanying prospectus, the registration statement, and the other documents that the Company has filed with the Securities and Exchange Commission for more complete information about the Company and this offering. Investors may obtain these documents for free by visiting the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, and Canada and elsewhere.

About Forward Looking Statements

This press release includes statements that may constitute “forward- looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the successful completion of the proposed offering on the anticipated terms or at all, the underwriters’ exercise of the over-allotment option, the Company’s use of the proceeds of the offering, successful finalization of the Company’s previously announced extension of its revolving credit facility with Silicon Valley Bank on terms acceptable to the Company and to the bank, completion of any extension of the shareholder guarantee of such facility, continued acceptance for the Company’s products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

SOURCE: Stereotaxis, Inc.

di Giancarlo Nicoli

Stereotaxis Receives Commitment to Increase and Extend Its Credit Facility With Silicon Valley Bank.

ST. LOUIS, Oct. 7 /PRNewswire-FirstCall/ — Stereotaxis, Inc. (Nasdaq: STXS) today announced that it has received a commitment letter from Silicon Valley Bank, a member company of SVB Financial Group (Nasdaq: SIVB), to increase and extend its credit facility. Under the terms set forth in the commitment letter, the Company could borrow up to $30 million, compared with $25 million under its current facility. Consistent with the current agreement, the revolving line of credit would include a sublimit of $10 million for advances guaranteed by two current shareholders. The facility would be extended for another year and would mature on March 31, 2011.

The commitment is subject to completion of definitive loan documents and other typical closing conditions. In addition, Stereotaxis also reported that it is in discussions with the shareholder guarantors regarding the final terms of a proposed extension of their $10 million guaranty facility to March 31, 2011.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, and Canada and elsewhere.

About Silicon Valley Bank

Silicon Valley Bank is the premier commercial bank for companies in the technology, life science, venture capital/private equity and premium wine industries. SVB provides a comprehensive suite of financing solutions, treasury management, corporate investment and international banking services to its clients worldwide. Through its focus on specialized markets and extensive knowledge of the people and business issues driving them, Silicon Valley Bank provides a level of service and partnership that measurably impacts its clients’ success. Founded in 1983 and headquartered in Santa Clara, Calif., the company serves clients around the world through 27 U.S. offices and international operations in China, India, Israel and the United Kingdom. Silicon Valley Bank is a member of global financial services firm SVB Financial Group (Nasdaq: SIVB), with SVB Analytics, SVB Capital, SVB Global and SVB Private Client Services. More information on the company can be found at www.svb.com.

Silicon Valley Bank is the California bank subsidiary and the commercial banking operation of SVB Financial Group. Banking services are provided by Silicon Valley Bank, a member of the FDIC and the Federal Reserve. SVB Private Client Services is a division of Silicon Valley Bank. SVB Financial Group is also a member of the Federal Reserve System.

About Forward Looking Statements

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the execution and delivery of final documentation of the revolving credit facility with Silicon Valley Bank on terms acceptable to the Company and to the bank, the ability of the Company to negotiate the terms of any extension of the insider guarantee discussed herein, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

SOURCE: Stereotaxis, Inc.

di Giancarlo Nicoli

Next Page →

• Search for:

• Seeking Alpha Gold Certification

  

  
  
  
  
  
  
  
  

• Spam Blocked

  139 spam comments blocked by
  Akismet

• Categorie

  • A Como e dintorni
  • A Milano
  • Alimentazione
  • Appiano Gentile
  • Attacchi di cani a persone
  • Beppe Grillo sì e no
  • Celiachia
  • Cinema
  • Comprare sembra facile
  • Dendreon
  • Girare in giro, mangiare, bere, divertirsi
  • Il mestiere di farmacista
  • Il Rosso e il Verde
  • Investimenti
  • Letterature
  • Liberista
  • Libertà
  • Libri che sto scoprendo
  • Marketing
  • Mondo cane
  • Mondo Internet
  • Persone
  • Politica
  • Start Up e Venture Capital
  • Stereotaxis
  • Stili di vita
  • Te lo do io il Brasile
  • Tutto il resto
  • TV

• Pubblicità

• Meta

  • Register
  • Log in
  • Entries RSS
  • Comments RSS
  • WordPress.org

• Pubblicità: Amazon.it

• Creative Common License

  
  Questo/a opera è pubblicato sotto una Licenza Creative Commons